What Comes After T-DXd in HER2+ Metastatic Breast Cancer?

When first-line therapy delivers years of disease control, sequencing becomes the next challenge.

When our most effective therapy is used first, the question isn’t just “what’s next,” but how to maintain disease control long-term. This clip explores the transition beyond T-DXd and why understanding the evolving biology of the disease is the key to choosing the next move.